Murray Hill, NJ -- June 28, 2001 -- C. R. Bard, Inc. (NYSE-BCR) today announced it had received Food and Drug Administration (FDA) approval to market the Bard Stinger™ S ablation catheter for the treatment of cardiac arrhythmias. The new ablation catheter offers a firmer distal tip than the standard Stinger ablation catheter, resulting in greater column strength and catheter tissue contact. The feature provides unique characteristics that allow the electrophysiologist to treat arrhythmias in various cardiac anatomies presented by the patient.
"The approval of our Stinger™ S ablation catheter underscores Bard's overall leadership in the electrophysiology market," said Bard chairman and chief executive officer, William H. Longfield, "and demonstrates our proven ability to develop new and innovative products to diagnose and treat abnormalities of the heart."
Ablation catheters are used to eliminate short circuits in the heart tissue that cause the heart to beat rapidly. This is accomplished by applying radiofrequency (RF) energy, the most widely accepted energy source used for cardiac ablation, through the catheter, directly to the tissue of the heart to destroy the circuit(s) causing the problem. After a successful RF ablation procedure, patients are usually discharged from the hospital either the same day or the next day and will generally resume normal work and physical activity without any restrictions. The current global market is estimated to be in excess of $100 million.
A unique combination of technology, comfort and functionality, the Stinger, Stinger M and Stinger S ablation catheters provide features and capabilities that enhance controlled endocardial ablation. Since pioneering clinical electrophysiology with the first His bundle recordings (electrical recordings taken from inside the heart) taken more than 30 years ago, Bard has been providing reliable, innovative products to the EP marketplace. Today, Bard Electrophysiology is the only company offering a full line of diagnostic and therapeutic catheters and a computerized EP recording system.
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of health care products in the fields of vascular, urology, oncology and surgical specialty products.